Skip to content

Home Map The News Technology Politics Business Sports Entertainment Science Health World

Global AI-Powered News Intelligence. Real-time headlines, mapped by continent and country, from news sources worldwide.

Powered by AI

Navigate

Home
Map The News
About
Sources & methodology
Sources & methodology
Search

Sections

Technology
Politics
Business
Sports
Entertainment
Science

More

Privacy
Contact
Sitemap
Robots

© 2026 newsGlobal. All rights reserved.

Headlines refresh every 10 minutes.

Home Map Search Topics About

Home / Business

Business

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Guardian

BusinessThe Guardian·Aug 3, 2026·1 min read

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts…

View original source — The Guardian ↗

ShareShare on X Share on Facebook

Related stories

Cyclospora outbreak is linked to two deaths in Michigan as case counts continue to rise

BusinessAug 3, 2026 · 1 min

Cyclospora outbreak is linked to two deaths in Michigan as case counts continue to rise

BusinessAug 3, 2026 · 1 min

Iran War Risk Still Important in Background, Says Torsten Slok

BusinessAug 3, 2026 · 1 min

A trio of positive developments has Boeing shares soaring

BusinessAug 3, 2026 · 1 min

Japan’s Use of Fed Tool Could Test Yen Resolve, Evercore Says